These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 12211411)

  • 21. Overview: from heparin to low molecular weight heparin: beyond anticoagulation.
    Mousa SA; Fareed J
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1077-80. PubMed ID: 11892916
    [No Abstract]   [Full Text] [Related]  

  • 22. Antithrombotic drugs in vascular medicine: a historical perspective.
    Schrör K
    Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy of heparin fractions: issues and answers.
    Messmore HL
    Crit Rev Clin Lab Sci; 1986; 23(2):77-94. PubMed ID: 2419035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor xa activity as a pharmaceutical mechanism and a yardstick for therapy.
    Béguin S; Welzel D; Al Dieri R; Hemker HC
    Haemostasis; 1999; 29(2-3):170-8. PubMed ID: 10629396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of cancer-associated thrombosis: distinguishing among antithrombotic agents.
    Pruemer J
    Semin Oncol; 2006 Apr; 33(2 Suppl 4):S26-39; quiz S41-2. PubMed ID: 16638458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anticoagulant and antithrombotic effects of low molecular weight heparin].
    Bashkov GV; Kalishevskaia TM; Bako N
    Biull Eksp Biol Med; 1988 Oct; 106(10):399-402. PubMed ID: 2847825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biochemistry and pharmacology of low molecular weight heparin.
    Rosenberg RD
    Semin Hematol; 1997 Oct; 34(4 Suppl 4):2-8. PubMed ID: 9399404
    [No Abstract]   [Full Text] [Related]  

  • 28. New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin.
    Martínez-González J; Rodríguez C
    Expert Rev Cardiovasc Ther; 2010 May; 8(5):625-34. PubMed ID: 20450295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Reversal for heparins and new anticoagulant treatments].
    Kortchinsky T; Vigué B; Samama CM
    Ann Fr Anesth Reanim; 2013 Jan; 32(1):37-49. PubMed ID: 23273505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Covalent antithrombin-heparin complexes.
    Patel S; Berry LR; Chan AK
    Thromb Res; 2007; 120(2):151-60. PubMed ID: 16978685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heparin: from animal organ extract to designer drug.
    Middeldorp S
    Thromb Res; 2008; 122(6):753-62. PubMed ID: 17996279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current use of low molecular weight heparins.
    Donayre CE
    Semin Vasc Surg; 1996 Dec; 9(4):362-71. PubMed ID: 8958613
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pharmacologic and clinical principles for rational anti-thrombotic preventive treatment with low molecular weight heparin].
    Pindur G; Köhler M; Heiden M; Leipnitz C; Rupp KH; Wenzel E
    Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir; 1990; ():1149-55. PubMed ID: 1983502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heparin and low molecular weight heparin: is anti-factor Xa activity important?
    Lane DA; Ryan K
    J Lab Clin Med; 1989 Oct; 114(4):331-3. PubMed ID: 2551984
    [No Abstract]   [Full Text] [Related]  

  • 35. Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer.
    Walenga JM; Lyman GH
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):1-18. PubMed ID: 23849978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin.
    Young E; Wells P; Holloway S; Weitz J; Hirsh J
    Thromb Haemost; 1994 Mar; 71(3):300-4. PubMed ID: 8029793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From heparins to factor Xa inhibitors and beyond.
    Alban S
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():12-20. PubMed ID: 15701143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-molecular-weight heparin--an opportunity for home treatment of venous thrombosis.
    Schafer AI
    N Engl J Med; 1996 Mar; 334(11):724-5. PubMed ID: 8594434
    [No Abstract]   [Full Text] [Related]  

  • 40. Unfractionated heparin and other antithrombin mediated anticoagulants.
    Adler BK
    Clin Lab Sci; 2004; 17(2):113-7. PubMed ID: 15168893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.